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Abstract
Pathway analysis provides a powerful approach for identifying the joint effect of genes grouped into biologically-based
pathways on disease. Pathway analysis is also an attractive approach for a secondary analysis of genome-wide association
study (GWAS) data that may still yield new results from these valuable datasets. Most of the current pathway analysis
methods focused on testing the cumulative main effects of genes in a pathway. However, for complex diseases, gene-gene
interactions are expected to play a critical role in disease etiology. We extended a random forest-based method for pathway
analysis by incorporating a two-stage design. We used simulations to verify that the proposed method has the correct type I
error rates. We also used simulations to show that the method is more powerful than the original random forest-based
pathway approach and the set-based test implemented in PLINK in the presence of gene-gene interactions. Finally, we
applied the method to a breast cancer GWAS dataset and a lung cancer GWAS dataset and interesting pathways were
identified that have implications for breast and lung cancers.
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Introduction
Many genome-wide association studies (GWAS) have been
conducted to identify markers associated with diseases over
millions of SNPs. However, to survive the multiple testing
correction over millions of tests, SNPs need to have strong
marginal effects on the disease or a large sample size is required for
SNPs with small effects. For a complex disease that is often caused
by the joint effects of multiple genes with small marginal effects,
considering the effects jointly will significantly increase the
statistical power to identify these genes. Pathway analysis provides
a powerful approach for identifying the joint effect of genes
grouped into biologically-based pathways on disease. Promising
pathway results have already been identified in GWAS datasets
[1–3].
Recently, many statistical pathway analysis methods have been
proposed. Most of them focused on testing the cumulative main
effects of genes in a pathway [4–6]. That is, pathway statistics were
derived based on single-marker association test statistics or p-
values. However, for complex diseases, gene-gene interactions are
expected to play a critical role in disease etiology. Some methods,
such as ‘‘Gene set Ridge regression in Association studies’’
(GRASS) [6], which is based on a regression framework, can
incorporate gene-gene interactions in the test. However, since
there are many combinations of SNPs for interactions, it is not
straightforward to select the combinations of SNPs in the
regression model to account for gene-gene interactions.
Random Forest (RF) has been used as a tool for association tests
[7,8]. SNPs are used as predictor variables and disease status is the
outcome in a classification tree. A set of classification trees is
created based on replicates of samples generated by a bootstrap
approach in the RF algorithm. The significance of a SNP is then
evaluated based on its prediction ability for the disease outcome.
Moreover, interactions are implicitly modeled in RF as each path
of edges in the tree corresponds to a particular combination of
alleles that is associated with the disease status [9]. Therefore,
several studies also applied RF to test gene-gene interactions
[10,11]. RF is efficient for a gene-gene interaction analysis, since a
small set of SNPs is used in each node of the tree for splitting the
samples.
RF has also been shown to be useful for pathway analysis due to
its promising feature of considering both main effects and gene-
gene interactions. Pang et al. identified candidate pathways by
ranking the pathways using their prediction error rates calculated
in RF for gene expression data [12]. Chang et al. performed a pilot
study of applying RF to SNP data for identifying pathways
associated with Glioma [13]. A permutation procedure was used
to estimate the p-value for each pathway by testing the significance
of the prediction error rate calculated based on a set of SNPs
within the pathway with respect to the error rates observed by
chance. Although RF was demonstrated to be a useful approach
for pathway analysis of SNP data in Chang et al., its statistical
power for analyzing SNP data has not been evaluated by
simulation studies. Moreover, a large pathway can have hundreds
of genes, which can include thousands of markers. To test a large
pathway for association, using all SNPs in the pathway for the RF
pathway analysis may reduce the classification power, as more
noise is introduced to the model. Reducing the number of SNPs
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can significantly increase the power for RF.
Here we propose a powerful two-stage RF-based pathway test
(TRF-pathway) based on SNP data, such as data from a GWAS.
We used simulations to verify that the TRF-pathway has the
correct type I error rates. We also compared the power of the
TRF-pathway to the original RF-based pathway test used in
Chang et al. Finally, we applied the TRF-pathway to a breast
cancer GWAS dataset and a lung cancer GWAS dataset and the
TRF-pathway identified candidate pathways that have implica-
tions for breast and lung cancer etiology.
Methods
In the RF algorithm [14], a training set of samples are selected
by sampling with replacement from the original samples. The
training set is used to create a classification tree, and the remaining
samples that are not in the training set are used as the testing set
for the classification tree. The process is repeated a large number
of times so that a forest of classification trees is created. Based on
the forest of trees, a sample that is classified more often in a
category (when it is in the testing set) is assigned to the category. A
classification error rate can then be calculated based on the
number of samples that are incorrectly classified. Moreover, the
significance for each predictor variable can be assessed by a
permutation procedure in RF. The variable importance is
standardized to a Z score.
We incorporated the RF algorithm in the TRF-pathway test.
SNPs in genes in a pathway are used as predictor variables to
classify the case and control status in RF. For a large pathway,
using SNPs in all the genes in the pathway may reduce the power
for classification, because a majority of SNPs may not have effects
on the disease. Therefore, we used a two-stage approach to
eliminate the number of SNPs that may not have effects. The RF
algorithm is performed on all SNPs in a pathway at the first stage.
Then SNPs with variable importance scores greater than a user-
specified threshold are selected at the second stage and the RF
algorithm is performed only on the significant SNPs. The
algorithm for the TRF-pathway is described as follows:
The TRF-pathway algorithm
For each pathway, we perform the following steps in the TRF-
pathway algorithm:
1. Select a set of SNPs within a user-specified distance to genes in
a pathway.
2. RF is performed based on the set of SNPs and the standardized
variable importance score is calculated for each SNP.
3. SNPs with importance scores greater than a user-specified
threshold are selected as the important SNPs. RF is performed
again based on the important SNPs.
4. The prediction error rate, which is the proportion of samples
not correctly categorized, from the RF analysis in step 3 is used
as a score R for the pathway.
5. Permute the case-control affection status and repeat steps 2–4
K times. In each permutation i, the score Ri is calculated.




where I(S)=1 when the statement S is true and I(S)=0 when S
is false. The null hypothesis for the TRF-pathway is that none
of the SNPs in the pathway are associated with the disease.
Note that if the user does not specify a threshold for the variable
importance scores, all the SNPs within genes in a pathway are used for
RF analysis and the TRF-pathway algorithm is reduced to the RF-
based pathway algorithm used in Chang et al. [13]. In the following
text, we refer to the RF-pathway as the method used in Chang et al.
Unlike methods developed for GWAS data that compare test
statistics of genes in a pathway with respect to statistics for
background genes in the genome such as Wang’s method [1] and
‘‘Association LIst GO Annotator’’ (ALIGATOR) [5], the TRF-
pathway compares the test statistic (i.e. the prediction error) with
respect to the null distribution of the test statistic. Therefore, the
TRF-pathway is suitable not only for GWAS, but also for
candidate gene or candidate pathway studies.
Simulations
We conducted simulation studies to evaluate the type I error
rates and power for the TRF-pathway. We used genomeSIMLA to
simulate SNPs in genes in a pathway based on Affymetrix 550k
chip [15]. Linkage Disequilibrium (LD) structures for SNPs were
simulated based on a forward-time population simulator, which
accounts for random mating, genetic drift, recombination and
population growth rate, in genomeSIMLA [15]. We randomly
selected 50 genes as a pathway for the simulations. A total of 1,038
SNPs within 20 KB to the genes in the pathway were selected.
Three SNPs (X1, X2 and X3) with minor allele frequencies 0.25,
0.15 and 0.15, each in different genes, were used as disease loci. A
penetrance function similar to the one used in [16] was used to






where X is a vector of X1, X2, and X3, a is the parameter based on
the disease prevalence, b1, b2, and b3 correspond to the
conditional marginal effects for X1, X2, and X3, b4, b5 and b6
correspond to the conditional interaction effects for the second-
order interactions, and b7 models the conditional interaction
effects for the third-order interaction. Xi is equal to 1 in the
presence of at least one of the minor alleles at the locus i and equal
to 0 if no minor allele is present. The disease prevalence was
assumed to be 1%. We simulated 1,000 cases and 1,000 controls in
each replicate of the simulations. We refer to the settings of these
parameters (i.e. the number of genes in the pathway, the number
of disease loci, the disease prevalence, and the number of cases and
controls) as Scenario 1.
In addition to Scenario 1, we also changed the parameters one at
a time for a more comprehensive simulation study. For Scenario 2,
we simulated 500 cases and 500 controls. For Scenario 3, we
changed the disease prevalence to be 5%. For Scenario 4, we
simulated a larger pathway with 100 genes. A total of 1,527 SNPs
within 20 KB to the genes in the pathway were used. We
simulated an additional disease locus with a minor allele frequency
of 0.25 for the large pathway. The disease locus has only main
effects on the disease and the model for the other three disease loci
is the same as eq (1).
We downloaded the Random Jungle package [17], which
efficiently implements the RF algorithm, for the RF analysis in
steps 2 and 3 in the TRF-pathway algorithm. We specified K as
2000 in all of our simulations as well as in the real data analyses.
The default bootstrap procedure in the RF algorithm was used to
determine the relative proportions of the samples in the training
and test sets. To evaluate the type I error rates for the TRF-
pathway, the parameters (b1–b7) were all specified as 0. A total of
5,000 replicates of simulated datasets were used to calculate the
ð1Þ
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model (Model 1) with main effects only. The parameters b1, b2, and
b3 were specified as 0.92 and b4–b7 were specified as 0 in Model 1.
Then we simulated a multiplicative model similar to the model
used in Chatterjee et al. [16]. That is, b1, b2, and b3 were specified
as Q, b4, b5, and b6 were specified as 2Q, and b7 was specified as
3Q. Therefore, the joint effect of two or three markers was the
product of the main effects of the individual markers. Model 2,
Model 3, and Model 4 were simulated with Q equal to 0.18, 0.22,
and 0.26, respectively. A total of 500 replicates of simulated
datasets were used to calculate the power for each model.
We compared the power of the TRF-pathway with the RF-
pathway and the set-based test in PLINK [18]. All of the 1,038
SNPs were provided as a set in PLINK. TagSNPs selected based
on the LD measure r
2 of 0.5 were tested for association using a
standard chi-square test. The mean of the chi-square statistics for
SNPs with p-values ,0.05, which is the default setting in PLINK,
was used as the statistic for the pathway in PLINK. A permutation
procedure is used to create a null distribution for the statistic and
estimate the p-value. Therefore, the set-based test in PLINK does
not need background genes across the genome for the statistic. In
the following text, we refer to PLINK as the set-based test
implemented in PLINK. In all of the simulation models, we
specified the threshold as 1.64 for the variable importance scores,
which corresponds to p-value of 0.05 in a one-tailed Z-test, in step
3 in the TRF-pathway algorithm.
Results
Simulations
The type I error rates for the TRF pathway, RF-pathway and
PLINK at the 0.05 and 0.01 levels under different scenarios are
shown in Table 1. As shown in Table 1, the simulation results
suggested that the TRF-pathway and the RF-pathway both have
the correct type I error rates close to the 0.05 and 0.01 nominal
levels when b1–b7 were all specified as 0. The power comparisons
for the TRF-pathway with the RF-pathway and PLINK under the
4 scenarios were shown in Figure 1 at the significance levels of 0.05
and 0.01. In Figure 1 we can see that the TRF-pathway
consistently has more power than the RF-pathway for all models.
We can also see that PLINK can have more power than the TRF-
pathway in Model 1 and Model 2. PLINK can also have more
power than the RF-pathway in Models 1, 2, and 3 across the 4
scenarios. However, with the increased multiplicative effects of
gene-gene interactions in Model 3 and Model 4, the TRF-pathway
has significantly more power than PLINK. The results demon-
strate that by using a two-stage approach, the TRF-pathway can
improve power significantly when compared to the traditional RF-
pathway approach. Moreover, the RF-based pathway methods
can have more power than methods considering only main effects
in the presence of strong gene-gene interaction effects.
A breast cancer GWAS analysis
We applied the TRF-pathway to a breast cancer GWAS dataset
available at dbGaP [19,20]. The dataset consists of 1,145 cases
and 1,142 controls and 499,206 markers across the genome
genotyped on the Illumina 550K platform. All the samples are
Caucasian women. SNPs that are within 20 KB to a gene were
assigned to the gene. We downloaded pathway definitions from
the Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway
database for humans [21]. There were 208 pathway definitions
used for the analysis.
Since Random Jungle assumes that there are no missing
genotypes in the data, we imputed the missing genotypes in the
sample using fastPHASE [22]. Genotypes with the highest
likelihood were used to replace the missing genotypes. A total of
2,000 permutations were used to estimate the p-value for each
pathway in the TRF-pathway algorithm.
Table 2 shows the pathways with p-values ,0.01 identified by
the TRF-pathway for the breast cancer GWAS. We also showed
the number of genes and the number of SNPs used in step 3 in the
TRF-pathway algorithm for each pathway in Table 2. None of the
pathways in Table 2 can pass the Bonferroni threshold for multiple
testing correction. However, interestingly, aminoacyl tRNA
synthetases (AARSs) that are involved in the ‘‘Aminoacyl-tRNA
biosynthesis’’ pathway in Table 2 have been shown to have
implications for the etiology of breast cancer [23]. AARSs are
essential for protein synthesis, and function as regulators and
signaling molecules in biological processes [24]. One of the
AARSs, lysyl-tRNA synthetase (KRS), was found to be over-
expressed in the tumor regions of breast cancer patients [24].
A lung cancer GWAS analysis
We also applied the TRF-pathway to a lung cancer GWAS
dataset from the Cancer Prevention Study II Nutrition Cohort
(CPS-II) [25] available at dbGaP [20]. After QC, the dataset
consists of 663 cases and 642 controls and 496,761 markers
genotyped on the Illumina 550K platform. The subjects were
collected by the American Cancer Society between 1992 and 2001
across all U.S. states. The same procedures as the breast cancer
analysis were used to impute missing genotypes. The same
pathway definitions from KEGG were used for the analysis.
Table 3 shows the pathways with p-values ,0.01 identified by
the TRF-pathway for the lung cancer GWAS. Similar to Table 2,
we showed the number of genes and the number of SNPs used in
step 3 in the TRF-pathway algorithm for each pathway in Table 3.
Interestingly, the TRF-pathway identified the p53 signaling
pathway, which is associated with many human cancers, with p-
value 0.006. The MDM2 gene, which is a key negative regulator
of p53 activity, is a candidate gene for non-small cell lung cancer
[26]. The p53 and MDM2 genes have also been shown to interact
with smoking for lung cancer in a Chinese population [27].
Discussion
We developed the TRF-pathway, which is a powerful two-stage
RF-based pathway analysis method extended from the RF-
pathway. Unlike many pathway analysis methods that consider
only main effects of genes, the TRF-pathway considers both main
effects of genes and gene-gene interactions. We used simulations to
verify that both the TRF-pathway and the RF-pathway are valid
tests for pathway association under the null hypothesis that none of
the SNPs within a pathway are associated with the disease. We
Table 1. Type I error rates for the TRF-pathway, RF-pathway,
and PLINK set-based tests.
TRF-pathway RF-pathway PLINK
0.05 0.01 0.05 0.01 0.05 0.01
Scenario 1 0.048 0.012 0.049 0.009 0.052 0.012
Scenario 2 0.054 0.011 0.049 0.010 0.053 0.011
Scenario 3 0.058 0.011 0.047 0.010 0.047 0.009
Scenario 4 0.049 0.009 0.051 0.008 0.050 0.010
doi:10.1371/journal.pone.0036662.t001
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stage design, statistical power can be significantly increased in the
TRF-pathway compared to the RF-pathway.
Our power comparisons suggested that when there are only
main effects or the effects of gene-gene interactions are not strong
(i.e. Model 1 and Model 2), PLINK can have more power than the
TRF-pathway and RF-pathway. This is not surprising as PLINK
tests specifically for main effects. However, when the effects of
gene-gene interaction are strong, the TRF-pathway has signifi-
cantly more power than PLINK. Therefore, in practice, the TRF-
pathway should be used as a tool that is complementary to the
methods considering only main effects such as PLINK.
The score R, which is the prediction rate based on the SNPs
with importance scores greater than a threshold in a pathway,
should not be used as an unbiased prediction error rate for the
SNPs due to the selection bias of the SNPs in step 3 in the TRF-
pathway algorithm. We did not calculate the unbiased prediction
error rate for the SNPs in the TRF-pathway algorithm because the
purpose of the TRF-pathway is to test the association of SNPs in
the pathway. N-fold cross-validation technique can be used to
estimate the unbiased error rate for the important SNPs in step 3.
For example, based on a 10-fold cross-validation procedure, each
9/10 of the samples can be used in the first stage of the TRF-
pathway algorithm as a training set to find the significant SNPs.
The remaining 1/10 of the samples can be used as a test set to
Figure 1. Power comparison of the TRF-pathway with PLINK and RF-pathway at the 0.05 and 0.01 significance levels.
doi:10.1371/journal.pone.0036662.g001







T cell receptor signaling pathway (hsa04660) 97 105 0.001 0.168 0.035
Maturity onset diabetes of the young (hsa04950) 25 27 0.003 0.043 0.048
Prostate cancer (hsa05215) 82 90 0.004 0.143 0.012
Aminoacyl-tRNA biosynthesis (hsa00970) 39 56 0.009 0.016 0.252
1Number of genes in the pathway.
2Number of SNPs used in the step 3 in the TRF-pathway algorithm.
3P-values for the TRF-Pathway.
4P-values for RF-Pathway.
5P-values for PLINK set-based tests.
doi:10.1371/journal.pone.0036662.t002
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prediction error rate is the average of R over 10 replicates.
However, sample size will be reduced due to the partition of the
data. Our simulation suggested that this resulted in a significant
loss of power (Data not shown). Alternatively, an independent
dataset can be used to calculate the unbiased prediction error rate
for the significant SNPs in step 3 in the algorithm.
The significant results shown in Tables 2 and 3 for the breast
cancer and lung cancer GWAS analyses did not pass the
Bonferroni threshold for multiple testing correction. However,
tests for pathways are not independent because pathways can
share common genes. Therefore, the Bonferroni correction can be
conservative. Moreover, an interesting pathway (hsa00970)
identified by the TRF-pathway has been shown to have
implications for breast cancer etiology. The p53 pathway
(hsa04115), which contains candidate genes for lung cancer, was
also identified by the TRF-pathway. This demonstrates that the
TRF-pathway can be a powerful tool for identifying candidate
pathways associated with diseases.
Unlike some pathway methods that calculate gene-specific
scores for pathway statistics [1,6], the TRF-pathway uses all SNPs
within genes in a pathway for the joint inference without
considering gene-specific information such as gene sizes or
groupings of SNPs within genes. Power studies suggested that
pathway methods without calculating gene-specific statistics such
as PLINK can still be more powerful than methods that
specifically calculate gene scores [6]. However, it will be of
interest to know how gene-specific information can improve power
for the TRF-pathway. We are investigating how to incorporate
gene-specific information such as gene sizes and LD structures in
the RF model for pathway analysis.
In summary, we used simulations and applications to breast
cancer and lung cancer GWAS datasets to demonstrate that the
TRF-pathway is a powerful pathway analysis tool. The TRF-
pathway is implemented in a PERL script. The script uses the
PLINK software to generate input files for Random Jungle (with –
recodeA option) and uses Random Jungle for the RF calculations.
A more efficient program of the TRF-pathway using C++ will be
implemented so that the TRF-pathway can be applied to a large
set of pathways. The script is freely available at http://
sourceforge.net/projects/trfpathway/.
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